Company intelligence / Profile preview

Tether Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Tether Therapeutics has developed a proprietary polymer nanoparticle platform enabling inhalable mRNA therapies for severe respiratory diseases. Their preclinical data demonstrate orders-of-magnitude higher protein expression in the lungs compared to lipid nanoparticles (LNPs), with good tolerability in rodent and non-human primate models. The technology has shown translatable delivery across six species and can carry various nucleic acid payloads. The company raised $5 million in seed funding after significant DARPA support (~$40 million) enabled foundational research at Georgia Tech/Emory University labs. No clinical results are available yet as the programs remain preclinical.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: mRNA therapeutics (inhalable)Polymeric nanoparticles for gene delivery
Industry: Biotech

Beyond the preview

Go deeper on Tether Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tether Therapeutics.

Explore the full profile